On 17 June, REVERA Law Group invites pharmaceutical companies to a business breakfast on permanent establishments and monitoring the presence of foreign companies.
The event is closed‑door.
During the meeting, REVERA Law Group experts will outline practical steps on:
1. how to determine the boundary between a non‑commercial presence and a permanent establishment,
2. which indicators regulatory authorities monitor, and
3. how to safely structure a presence model.
Why We Are Holding This Meeting
REVERA works with foreign pharmaceutical companies in Belarus and understands the dynamics of the pharmaceutical market. We have observed that some representative offices operate under models which, if they breach the restrictions on commercial activity, create real tax risks and risks for local management.
The Belarusian pharmaceutical market operates under long‑standing norms: the concept of a representative office of a foreign company is a familiar form of commercial presence. Tax authorities increasingly identify signs of a permanent establishment, although such cases often arise outside the pharmaceutical sector. Nevertheless, there are a number of situations in pharma where a presence has been recognised as a permanent establishment, which can lead to significant fiscal and compliance consequences.
This business breakfast is not a public seminar. It is an opportunity for a focused discussion on real market dynamics, sector‑specific compliance challenges, and actionable steps attendees can take now.
